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Abstract: Solid lipid nanoparticles (SLN) present low toxicity, versatility to incorporate both lipophilic
and hydrophilic drugs, controlled drug release and they are easy to scale-up. It is well known that
the endocytosis pathway by which SLN are taken up and the subsequent subcellular distribution
are crucial for the biological effect of the incorporated drug. In addition, interactions between SLN
and cells depend on many factors, such as, the composition of nanoparticle surface. In this work
different amounts of phosphatidylethanolamine polyethylene glycol (PE–PEG) were added to SLN
composed of stearic acid, Epikuron 200 and sodium taurodeoxycholate. Characterization of obtained
nanoparticle suspensions were performed by the analysis of particle size, polydispersity index,
ζ-potential, cell toxicity and cell internalization pathway. We have observed that the presence of
PE–PEG improves active cell internalization of the nanoparticles in an oral adenocarcinoma cell
line, reducing non-specific internalization mechanisms. Finally, we have tested the effect of surface
coating on the efficiency of incorporated drugs using all-trans retinoic acid as a model drug. We have
observed that delivery of this drug into PE–PEG coated SLN increases its chemotoxic effect compared
to non-coated SLN. Therefore, it can be concluded that surface modification with PE–PEG improves
the efficiency and the specificity of the SLN-loaded drug.
Keywords: solid lipid nanoparticles; phosphatidilethanolamine–polyethileneglycol; controlled drug
delivery; cell internalization pathway; cytotoxicity; all-trans retinoic acid
1. Introduction
A well-designed drug delivery system (DDS) should be able to improve drug solubility and
permeability, avoiding drug degradation or fast elimination. In addition, it is expected to selectively
carry a drug into its targeted tissue (or cell type), improving drug efficiency and reducing side effects.
Hence, development of novel DDS to achieve the best therapeutic results has become a big challenge
for the last decades [1]. In general terms, nanotechnology has abruptly broadened the field of DDS and
particularly solid lipid nanoparticles (SLN) have emerged as some of the most promising nanocarriers
for controlled drug delivery in the treatment of complex diseases (i.e., cancer or brain pathologies) [2,3].
SLN are submicron-sized dispersions composed of a solid lipid core and a surfactant (and in
some cases a co-surfactant), which surrounds the lipid core and helps the assembly of lipophilic
components in an aqueous solution. SLN present many advantages in comparison to other drug
delivery systems. They are able to incorporate hydrophilic and lipophilic drugs, present no biotoxicity
and their production can be easily scaled up [2,4,5]. Because of their solid core, drug release is controlled
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and they can prevent drug degradation due to solvent contact [6]. Their size and liposolubility enables
drug diffusion through some biological barriers, including blood–brain barrier [7,8] and they are not
readily taken up by cells of the reticuloendothelial system, so that their filtration in liver or spleen
is reduced [9]. Of particular interest is the fact that SLN tend to accumulate preferentially in tumor
tissues versus normal tissues due to the so-called “enhanced permeability and retention effect” [10].
Taking together all these attractive characteristics, SLN seem to be a powerful tool for drug delivery to
tumors, contributing to improve chemotherapeutic strategies.
Another critical point concerning chemotherapy is the capability of some cancer cells to develop
multidrug resistance (MDR). The MDR phenotype observed in many malignancies is frequently
associated with the overexpression of P-glycoprotein (P-gp) and other membrane transporters [11].
In this regard, some promising results have shown that SLN are able to avoid this multidrug resistance
mechanism, increasing intracellular drug concentration [12] especially when SLN are internalized
by endocytosis [13–15]. Therefore, SLN internalization pathway is crucial for the efficiency of the
drug and the success of the treatment. Additionally, it is known that internalization pathway depends
on some factors such as particle size, morphology, composition, hydrophilicity and cell type [16].
Although this type of nanoparticles have demonstrated their capacity to improve drug efficiency,
little is known about the mechanism by which SLN enter different cell types. Unfortunately, there is
no general rule to predict the internalization pathway for a given SLN composition in a specific cell
type. Taking into account the relevance of the uptake mechanisms in the subcellular distribution of a
given drug and the implications of the internalization pathway in the efficiency of the treatment, more
detailed studies should be addressed in this direction.
Previous investigations have established that a very relevant factor in the clinical use of
nanoparticles is their half-life in circulation. It has been reported that surface coating with hydrophilic
molecules such as polyethyleneglycol (PEG) can avoid nanoparticle opsonization and uptake by
immune cells, reducing nanoparticle clearance by the reticuloendothelial system and improving
biological half-life of different DDS [17,18], including SLN [19,20]. Apart from enhancing circulating
half-life of different DDS, PEG addition (or PEGylation) can also improve nanocarrier characteristics by
stabilization of nanoparticle suspensions, reducing toxicity and improving biocompatibility (reviewed
in [21]). Nonetheless, it has to be taken into account that the effect of PEGylation in pharmacokinetic
characteristics of the nanoparticles depends on many factors such as PEG molecular weight, density and
conformation [21]. For instance, Yang and coworkers demonstrated that PEGylation of nanoparticles
should be relatively high-densed to achieve “stealth” properties [22]. Therefore, to obtain a suited DDS
for a particular therapeutic treatment, among other factors, the impact of the surface modification on
the uptake mechanism of different cells should be studied for each nanoparticle composition. This is
particularly relevant when the internalization pathway of the chemotherapeutic drug is fundamental
for drug efficiency, as mentioned before.
In the context of controlled drug delivery, apart from endocytic pathways, other drug
internalization mechanisms should be taken into account too. In this regard, it has been described that
lipophilic cargos can be transferred from nanocarriers to membranes by a direct interaction [23,24].
Hofmann and coworkers described that a temporary interaction between nanoparticles and membranes
can facilitate the release of hydrophobic molecules, which eventually localize into lipid droplets [25].
This mechanism, known as “kiss-and-run”, is unspecific and stochastic and should be avoided.
It involves the transfer of the cargo from the nanocarrier to any membrane inside the organism.
The prevention of a direct interaction between nanoparticles and cell membranes should reduce
“kiss-and-run” mechanism. To this aim, modification of nanoparticle surface with PEG could impede a
direct interaction between nanoparticle and unspecific cell membrane, reducing unwanted transfer of
the cargo. Thus, PEGylation could improve the efficiency of the DDS.
Consequently, to study the effect of PEG coating on SLN characteristics we modified the surface
of a promising SLN composition, which had been previously applied to improve the efficiency of a
calendula extract treatment [26]. We coated SLN with phosphatidylethanolamine–polyethileneglycol
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(PE–PEG) at different PEG densities. The best SLN composition based on their physicochemical
characteristics was selected and the interactions between SLN suspension and two different human
cell lines: an oral squamous carcinoma cell line (SCC-25) and a leukemia derived monocyte cell line
(THP-1) were analyzed. We observed that PEG modification did not change interaction between SLN
and THP-1 cells, but it was a critical factor in the cell internalization mechanism in SCC-25 cells. Finally,
we studied the implication of this surface modification in the efficiency of a drug treatment. For this
purpose, we selected all-trans-retinoic acid (ATRA) as a model drug, a well-known chemotherapeutic
drug [27], and we studied the efficiency of this drug when incorporated into SLN and into PEG–SLN.
As a result, we concluded that PE–PEG coating improves the efficiency of the drug in comparison to
not only free ATRA but also when it is vehiculized in SLN.
2. Materials and Methods
2.1. Materials
Stearic acid (SA) (≥98.5%), sodium taurodeoxycholate hydrate (≥95%), all-trans retinoic
acid (≥98%, ATRA), RPMI-1640 medium, DMEM:HAM’S F-12 medium, cytochalasin D, filipin
and chlorpromazine were purchased from Sigma-Aldrich (St. Louis, MO, USA). Epikuron
200®(containing about 95% soy phosphatidylcholine, PC) was kindly provided by Cargill
(Minneapolis, MN, USA). Amicon Ultra-15 centrifugal filter units were obtained from Millipore
(Darmstadt, Germany) and water from a Millipore Milli-Q®ultrapure water purification unit was
used. The 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000]
(DSPE-PEG2000) was purchased from Avanti Polar Lipids (Alabaster, AB, USA). Gibco™
Penicillin-Streptomycin-Glutamine (100X), 5-dodecanoylaminofluorescein (C12-FITC), octadecyl
rhodamine B (R18) and 4,6-diamidino-2-phenylindole (DAPI) were obtained from Thermo Fisher
Scientific (Waltham, MA, USA). CytoTox 96®Non-Radioactive Cytotoxicity Assay was obtained from
Promega (Madison, WI, USA) and 96-well microtiter plates from Sarstedt (Nümbrecht, Germany).
2.2. Preparation of Solid Lipid Nanoparticles
SLN were prepared by the warm microemulsion technique [26]. Briefly, an oil/water (o/w)
microemulsion was prepared mixing stearic acid (0.070 mmol), Epikuron 200®(0.014 mmol), sodium
taurodeoxycholate (0.066 mmol) and ultrapure water as the continuous phase (11.11 mmol). Stearic
acid and Epikuron 200®were first melted together at 80 ◦C under continuous stirring (1400 rpm).
The aqueous phase and the taurodeoxycholate were heated to the same temperature and added to
the melted lipid mixture. The mixture was stirred until a transparent, thermodynamically stable
microemulsion system was formed. This hot microemulsion was then dispersed into cold water
(2–4 ◦C) using a 1:50 ratio (microemulsion:water, v/v) under vigorous stirring (14,000 rpm for 10 min)
with a SilentCrusher M, Heidolph Instruments (Schwabach, Germany) to form a SLN dispersion. Then,
samples were washed three times using Amicon Ultra-15 centrifugal filter units (molecular weight
cut-off 100 kDa, Millipore, Billerica, MA, USA) and appropriately diluted in ultrapure water for the
following determinations.
Fluorescent probes or PE–PEG were added to the lipid mixture to develop fluorescent SLN (fSLN)
or PE–PEG-coated SLN (PEG–SLN). SLN loaded with all-trans retinoic acid were obtained by adding
the drug to the melted lipid mix just before aqueous phase addition in order to minimize possible
heat-derived drug degradation.
For sterilization purposes, SLN suspensions were passed through 0.22 µm pore filters.
2.3. Photon Correlation Spectroscopy
The average diameter and polydispersity index of SLN dispersions were determined by photon
correlation spectroscopy (PCS) using a Zetasizer Nano S (Malvern Instruments; Malvern, UK).
ζ-potential was determined from electrophoretic mobility using a Zetasizer Nano ZS (Malvern
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Instruments; Malvern, UK). Each sample was measured in triplicate at 25 ◦C after dilution with
ultrapure water to obtain appropriate concentration.
2.4. Transmission Electron Microscopy
Transmission electron microscopy (TEM) analysis was performed using a Philips EM208S
microscope in the Analytic and High Resolution Microscopy in Biomedicine Unit of the General
Research Services (SGIKER) of the University of the Basque Country (UPV/EHU). TEM samples were
diluted 1:20 with ultrapure water and stained with uranyl acetate before analysis.
2.5. Incorporation of All-Trans Retinoic Acid in SLN
After forming and washing ATRA-containing SLN dispersions, ATRA–SLN were filtered through
0.45 µm pore filters in order to discard other non-colloidal populations.
Once these SLN were purified, the incorporation of ATRA was determined by measuring the
drug content of the obtained suspensions by spectrophotometry. Briefly, suspensions were dried and
dissolved in chloroform:methanol (1:1). Sample absorbance was measured at 351 nm and concentration
values were obtained using a calibration curve built with ATRA solutions.
Entrapment efficiency (EE) was calculated applying the following formula:
EE = (ATRA amount in SLN)/(Initial ATRA amount) × 100
2.6. Cell Culturing
The SCC-25 and THP-1 cell lines used in this work were purchased from American Type Culture
Collection (ATCC, Manassas, VA, USA). SCC-25 cells are oral squamous carcinoma cells and they were
cultured under standard conditions (humidified atmosphere of 5% CO2 at 37± 1 ◦C) in DMEM:HAM’S
F-12 supplemented with 400 ng/mL hydrocortisone, 10% heat-inactivated fetal bovine serum (FBS),
50 mg/L penicillin-streptomycin and 0.1 g/L L-glutamine.
THP-1 cells, a human monocytic cell line, were cultured under standard conditions in RPMI-1640
medium supplemented with 10% FBS, 50 mg/L penicillin-streptomycin and 0.1 g/L L-glutamine.
For in vitro experiments with cells, SLN were added in serum-free medium in order to avoid
protein adsorption related phenomena [28–30] and to obtain a more controlled system to observe
interactions between SLN and cells.
2.7. In Vitro Cell Cytotoxicity Assay
Cytotoxicity of SLN preparations was tested in human THP-1 and SCC-25 cells by measuring
the release of the cytosolic enzyme lactate dehydrogenase (LDH). The quantitative measurement of
LDH activity was performed using the CytoTox 96®Non-Radioactive Cytotoxicity Assay according to
manufacturer’s instructions (Promega, Madison, WI, USA). In order to obtain total cell cytotoxicity
(0% viability) cells were lysed using 0.8% Triton X-100. Untreated cells were used as negative controls.
Cytotoxicity (%) of applied treatments was calculated using the following formula:
Cytotoxicity (%) =
(sample absorbance− control absorbance)
(lysed cell absorbance− control absorbance) × 100 (1)
To establish CC50 dose (the SLN concentration that kills 50% of cell population), four-parameter
logistic nonlinear regression analyses were performed. Cytotoxicity dose-response curves were plotted
using GraphPad Prism 5 software (GraphPad Software Inc., San Diego, CA, USA). The curve equation
was calculated applying the following formula:
Y =
100(
1 + 10((logCC50−x)∗HillSlope
) (2)
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2.8. Cell Incorporation Assay by Flow Cytometry
5-dodecanoylaminofluorescein (C12-FITC) probe was used in flow cytometry experiments
because it is a useful tool to distinguish between uptaken and internalized fluorescent signal in
cell incorporation experiments. Trypan-blue can quench C12-FITC emitted fluorescence but it cannot
enter live cells [31]. Therefore, in a cell suspension with trypan-blue only fluorescence signal of cell
internalized fluorescein can be detected. Fluorescence intensity of samples treated with trypan blue
was considered as fluorescence from internalized fSLN and fluorescence of samples without trypan
blue treatment was considered as cell uptake (attached and internalized fSLN).
SCC-25 cells were seeded in 6-well plates at 1.5 × 105 cells/well cell density. The next day,
cells were washed and incubated in serum-free medium. Appropriate concentrations of fSLN
suspensions were added and cells were further incubated during different time periods. Then,
cells were washed and harvested by trypsinization. THP-1 cells were seeded in 24-well plates at
105 cells/well in serum-free medium. Appropriate concentrations of fSLN suspensions were added
and cells were further incubated during different time periods. Cells were then harvested and washed
by centrifugation (5 min, 500× g).
To achieve endocytosis inhibition assays, cells were incubated with the corresponding inhibitory
drugs during half an hour before the addition of fSLN suspension.
Geometrical mean of the fluorescence intensity of cell populations was measured by flow
cytometry with an air-cooled 488 nm argon–ion laser (FACSCalibur, BD Biosciences; San Jose,
CA, USA) and CellQuest software (Becton Dickinson; Franklin Lakes, NJ, USA), according to the
manufacturer’s instructions.
2.9. Cell Incorporation Assay by Confocal Microscopy
For confocal microscopy experiments fSLN were obtained by adding octadecyl rhodamine
B (R18) to the lipid mixture. SCC-25 cells were seeded on 12-mm glass coverslips that were
placed inside 24-well plates at 104 cells/well cell density. The next day, cells were washed and
incubated in serum-free medium. fSLN suspensions were added and cells were further incubated
during different periods of time. At the given time, cells were washed and fixed for 30 min using
paraformaldehyde (4% in phosphate buffered saline (PBS)). After washing the cells, nuclei were stained
using 0.5 µg/mL DAPI and coverslips were mounted using ProLong™ Glass Antifade Mountant
(Invitrogen, Walthan, MA, USA). Images were obtained using an inverted confocal fluorescence
microscope (Nikon D-ECLIPSE C1, Nikon Inc., Melville, NY, USA) with a total internal reflection
fluorescence ×60 oil immersion objective. The excitation wavelengths used were 488, 561, and 635 nm,
and emitted fluorescence was recorded using band pass filters of BP515, BP593, and a long pass filter
of LP650, respectively. Fluorescence images were processed with ImageJ software (National Institutes
of Health, Bethesda, MD, USA).
2.10. Statistical Analysis
Statistical analysis was performed using the two-tailed, paired Student’s t-test, where p < 0.05
was considered to be significant (GraphPad Prism software, San Diego, CA, USA).
3. Results
3.1. Development and Characterization of PE–PEG Coated SLN
In order to analyze physicochemical characteristics of PEG–SLN we developed different SLN
suspensions obtained by adding different amounts of PE–PEG. For this purpose, we substituted a
percentage of Epikuron 200 (phosphatidylcholine, PC) with PE–PEG molecules in the initial lipid
mixture of the microemulsion formation. Therefore, 1% PE–PEG means that 1% of PC moles have been
substituted with the same moles of PE–PEG.
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We prepared four different nanoparticle suspensions (0, 1, 2 and 4% of PE–PEG) and determined
their size, polydispersity (pdi) and ζ-potential by photon correlation spectroscopy. Covering SLN with
PE–PEG marginally increased nanoparticle size and slightly decreased ζ-potential of nanoparticle
suspensions with 2% and 4% of PE–PEG (Figure 1).
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(a) Particle size, (b) polydispersity index (pdi) an (c) - te ti l l es f ifferent SLN were obtained
by Photon Correlation Spectroscopy. Results are the mean ± SEM of four independent experiments.
It has been reported that PEG coating increases stability of developed nanoparticle suspensions [32,33].
In order to test this feature we stored different suspensions of nanoparticles in distilled water at 4 ◦C
and we tested the main nanoparticle characteristics at different time points during 1 week. We observed
no significant differences in size, polydispersity (pdi) and ζ-potential of the SLN, concluding that
PE–PEG coating did not affect nanoparticle stability in these storage conditions (data not shown).
Next, we analyzed nanoparticle morphology by transmission electron microscopy and we
observed a similar morphology and size in coated and non-coated SLN suspensions (Supplementary
Figure S1).
It is well known that PEG coating reduces cytotoxicity of different DDS [34,35]. In order to study
the effect of PE–PEG coating, we tested cell cytotoxicity of different SLN suspensions performing
CytoTox 96®Non-Radioactive Cytotoxicity Assay in two different cell lines: a human monocytic
cell line THP-1 and a human epithelial cell line SCC-25. We observed that PEGylation reduced the
cytotoxicity of SLN cytotoxicity in both cell lines. Moreover, although the pattern was different, the
CC50 increased from 0% to 2% PE–PEG in both cell lines. Further increment was not observed for 4%
PE–PEG coating (Figure 2).Nanomaterials 2019, 9, x FOR PEER REVIEW 7 of 17 
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Figure 2. Cytotoxicity of different SLN suspensions in THP-1 and SCC-25 cell lines. (a) THP-1 cells were
seeded into 96-well culture plates at 2 × 104 cells/well. Then, different concentrations of non-coated
SLN (0%) (•) or SLN coated with different percentages of PE–PEG (1% (), 2% (N) or 4% (H)) were
added to cell culture. They were incubated for 24 h and cell toxicity was determined by CytoTox
96®Non-Radioactive Cytotoxicity Assay. Cell toxicity (%) was defined as mentioned in Materials
and Methods. Results are the mean ± SEM of three independent experiments performed in triplicate.
Dose-response curves were plotted using GraphPad. (b) SCC-25 cells were seeded into 96-well culture
plates at 104 cells/well. The next day, different concentrations of non-coated SLN (0%) (•) or SLN
coated with different percentages of PE–PEG (1% (), 2% (N) or 4% (H)) were added to cell culture and
cells were further incubated for 24 h. Cell cytotoxicity was determined by CytoTox 96®Non-Radioactive
Cytotoxicity Assay. Cell viability (%) was defined as mentioned in Materials and Methods. Results are
the mean ± SEM of five independent experiments performed in triplicate. Dose-response curves were
plotted using GraphPad. (c) CC50 of different SLN suspensions were obtained from dose-response
curves in THP-1 cell culture. (d) CC50 of different SLN suspensions were obtained from dose-response
curves in SCC-25 cell culture.
3.2. Incorporation of PEG–SLN in Cell Culture
Extensive analysis of cell incorporation pathway is essential to understand controlled drug
delivery, as this process determines drug fate inside the cell. To do so, fluorescent probe incorporation
can be analyzed by flow cytometry or confocal microscopy, measuring fluorescence intensity of each
cell in the culture. For this purpose, we incubated SCC-25 and THP-1 cells with fSLN and cell uptake
was defined as the total fluorescence intensity (coming from cell surface and inside the cells) and cell
internalization was the portion of the fluorescence signal coming from inside the cells.
In order to determine optimal incubation time and nanoparticle concentrations for internalization
pathway analysis, we performed concentration- and time-courses with non-coated fSLN by
flow cytometry.
Analysis of non-coated fSLN uptake by flow cytometry indicated that fSLN incorporation is
concentration and time dependent for THP-1 cells. We observed that fSLN cell internalization was
saturated at 0.5 mg/mL concentration and after 1.5 h of incubation (Figure 3a,b). When the same
analysis was performed for SCC-25 cells again cell internalization was saturated after 1.5 h of incubation
but concentration effect remained lineal (Figure 3c,d). In order to characterize interactions between
cells and fSLN, measurements must be performed at a dynamic range, so that the differences are more
obvious. Therefore, we decided to work at the range of fSLN concentration and incubation time were
cell internalization remains linear. These optimal conditions were 0.2 mg/mL of fSLN and 1 h of
incubation, for both cell lines.
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se ded at 105 cel s/ ( ) treate ith if erent concentrations of fSLN for 2 h or (b) treated with
0.25 mg/ L of fSLN for different incubation periods. SC -25 cells wer seed at 1.5 × 105 cells/well
in 6-well plates and incubated overnight. ext day, cel s were washed and treated with different
concentration of fSLN for 2 h (c) or incubated with 0.25 mg/mL fSLN for indicated periods of time
(d). Then, cells were washed in PBS and collected in order to measure GeoMean of the fluorescence
intensity (FI(GM)) of incorporated C12-FITC by flow cytometry. Samples measured without trypan
blue are indicated as cell uptake () and samples measured with trypan-blue are indicated as probe
internalization (N). Results are the mean ± Range of two independent experiments. Total binding
saturation curve was calculated in order to facilitate data reading.
3.2.1. PE–PEG Coating Improves Active fSLN Internalization Mechanisms in SCC-25 Cells but not in
THP-1 Cells
As mentioned before, SLN incorporation pathway must be determined to evaluate SLN suitability
as a DDS for chemotherapeutic drugs. Because endocytosis is an energy dependent internalization
mechanism, we wanted to study cell internalization of different nanoparticle suspensions in the
presence or absence of ATP. For this purpose, we analyzed cell internalization of fSLN in an ATP
depleted condition, using sodium azide treatment. We observed that ATP depletion affected to both cell
lines but in a different extent (Figure 4). In THP-1 cell line, fSLN internalization was almost blocked in
the presence of azide for all tested SLN suspensions. Intriguingly, the inhibition of cell internalization
by sodium azide was PE–PEG dependent for SCC-25 cells. Increasing PE–PEG percentage enhanced
the effect of ATP depletion, indicating that PE–PEG coating improves active (ATP dependent) cell
internalization pathways. Few differences in the ATP depletion effect were observed between 2% and
4% of PE–PEG; therefore, at this point we selected 2% PE–PEG SLN suspension in order to compare
SLN with or without PE–PEG coating in SCC-25 cells.
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washed and trypan blue was added in order to measure inte naliz d SLN fluorescence. Data are shown
as percentage of fSLN internalization relative to the values of internalization in the abse ce of sodium
azide. Results are the mean ± SEM of five independent experiments.
3.2.2. PE–PEG-Coating Does Not Alter Intracellular Distribution of SLN in SCC-25 Cells
Taking into account the impact of PE–PEG coating on cell internalization in SCC-25, we wondered
whether the subcellular distribution pattern could vary depending on the surface of the nanoparticles.
We analyzed by confocal microscopy the fluorescence intensity of fSLN with or without surface
modification. We observed no differences between the subcellular distribution of both nanoparticle
suspensions by this method (Figure 5). In both cases, nanoparticles were internalized at similar time
range and cell distribution of fSLN can be observed in the cytosol.Nanomaterials 2019, 9, x FOR PEER REVIEW 10 of 17 
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at 2 × 104 cells/well. The next day, cells were washed and incubated with 0.2 mg/mL of fPEG–S N (a)
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3.2.3. PE–PEG-Coating Affects Cell Internalization Pathway of fSLN in SCC-25 ells
We next wond red hether PE–PEG modification affected SLN incorporation pathway. Endocytosis
can be divi ed into two main categories: phagocytosis (accom lished by professional phagocytes) and
pinocytosis. Pinocytosis can be dived into four different mechanisms: clathrin-me iated endocytosis,
caveolae-mediated endocytosis, clathrin- and caveolae-independent endocytosis or macropinocytosis.
In order to understand the internalization mechanism involved in fSLN uptake, we incubated cells with
selective pharmacological inhibitors of the aforementioned internalization pathways. Filipin (5 µg/mL)
inhibits caveolae-mediated endocytosis [15], cytochalasin D (5 µg/mL) inhibits macropinocytosis and
phagocytosis [36] and chlorpromazine (5 µg/mL) inhibits clathrin-mediated endocytosis [37].
THP-1 is a human monocytic cell line, which means that these cells can internalize SLN using
phagocytosis. This cell line has been used to determine the ability of PEG-coating to abolish
phagocytosis of nanoparticles [22]. In our hands, internalization in THP-1 cells of SLN suspensions
with or without PEG coating showed same inhibition pattern. Their internalization was inhibited
mainly by cytochalasin D and some inhibition was also observed in chlorpromazine treated cells
(Figure 6a). Therefore, in THP-1 cells phagocytosis seemed the main internalization pathway and there
was some SLN internalization in a clathrin-dependent endocytosis pathway.
For SCC-25 cells, the internalization mechanism for PEG-coated or non-coated SLN was different,
as the effect of endocytosis inhibitors was also different. Internalization of non-coated SLN was hardly
inhibited by applied endocytosis inhibitors. Cytochalasin D was the only inhibitor able to reduce
cell internalization of non-coated SLN. Thus, macropinocytosis seemed to be the main endocytosis
mechanism for non-coated SLN. For PEG–SLN, the main internalization inhibition was obtained with
chlorpromazine treatment and to a minor extent with cytochalasin D. Therefore, clathrin-mediated
endocytosis was the major mechanism for the internalization of PEG–SLN (Figure 6b). From our results
we concluded that for SCC-25 cells PEG-coating changed internalization pathway, from a passive to an
active endocytosis mechanism. Thus, applying PEG-coating did not inhibit phagocytosis of SLN in
THP-1 cells but it was relevant for the internalization mechanism of SLN in epithelial cells.
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Figure 6. Effect of PE–PEG-coating in fSLN internalization pathway. (a) THP-1 cells were seeded at
105 cells a pre-incubated with vehicle (Ctrl), cold treatment (4 ◦C), 5 µg/mL cytochalasin D
(cyt D), 5 µg/mL filipin (filip) or 5 µg/mL chl rpromazine (chl r) for 30 min. Then, cells were treated
with 0.2 g/mL of indicated SLN suspensions and further incubated for 1 h. After that, cells were
was ed with PBS and fluorescence intensity of internalized C12-FITC was measured by flow cytometry;
(b) SCC-25 cells w re see ed at 1.5 × 105 cells/well in 6-well plates. Th next day, cells w r exposed
to the same treatment and they were harvested ith i t easure their fluorescence
intensity by flow cytometry. Data are shown as percentage of intensity of fluorescence related to the
values of internalization of C12-FITC at 37 ◦C (10 %). Results are the mean ± S of four independent
experiments. (* p < 0.05; * p < 0.01; * p < 0.001).
3.3. PEG Coating Improves the Efficiency of ATRA-Loaded SLN Treatment
In order to study the effect of surface coating in the efficiency of a delivered drug we analyzed
the cytotoxic effect of a well-known drug able to suppress tumor cell growth, all-trans retinoic acid
(ATRA) [38]. This compound is a Vitamin A derivative that is able to regulate cell proliferation and
stimulate cell differentiation in immune cells, and it has been reported to inhibit cell proliferation in
SCC-25 cells [39]. Unfortunately, this is a very hydrophobic substance so that organic solvents or DDS
are needed in order to add it to cell cultures [40]. Therefore, incorporation of ATRA in SLN could be a
good strategy to avoid the application of organic solvents while improving drug efficiency.
3.3.1. ATRA Can Be Easily Loaded into SLN Using an Organic Solvent-Free Method
First, we prepared SLN suspensions adding different amounts of initial ATRA (0.5, 1, 2, 3 mg).
We observed that ATRA addition significantly increased SLN mean diameter size. Nevertheless, all
developed SLN suspensions presented physical characteristics in the range for drug delivery purposes
(Supplementary Figure S2).
We also determined drug entrapment efficiency (EE) and the total amount of incorporated ATRA.
We observed that initial 1 mg ATRA addition presented the best entrapment results since the highest
amount of incorporated ATRA was obtained (0.539 ± 0.005 mg) and the EE was 53.92% ± 4.98, almost
the highest value obtained (Supplementary Figure S3).
Once we determined optimal ATRA loading, we modified SLN surface with PE–PEG in order to
compare the drug efficiency in these different DDS. Adding 2% of PE–PEG did not significantly change
SLN characteristics (Supplementary Figure S4) but slightly reduced ATRA entrapment efficiency from
54% ± 1.04 to 36% ± 4.51. Despite this reduction, total ATRA amount was high enough to study the
chemotherapeutic effect.
3.3.2. PEG–SLN Are More Efficient Drug Carriers than SLN without Surface Modification
We performed cell cytotoxicity experiments in order to measure the effect of ATRA dissolved in
ethanol or delivered in SLN or in PEG–SLN. We observed that the cytotoxic effect of ATRA at tested
concentrations (5 and 20 µM) (Figure 7) was higher when it was delivered in SLN in comparison to
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free ATRA. Specifically, its effect was significantly higher when ATRA was vehiculized in PEG–SLN.
The most pronounced difference between cytotoxic activities of tested delivery systems was observed
at 20 µM. At this concentration, free ATRA treatment showed a cytotoxicity effect of 21.16% ± 8.32
whereas SLN incorporated ATRA increased cytotoxicity to 55.74% ± 7.74 and PEG–SLN incorporated
ATRA increased cytotoxicity to 79.28% ± 10.51.
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4. Discussion
Solid lipid nanoparticles have demonstrated their ability to improve drug stability, solubility,
biodistribution and efficiency. Nonetheless, although their interactions with cell membranes play a
crucial role in drug delivery, remain broadly unexplored. It has been understood that internalization
mechanism depends on many factors and therefore, interactions between cells and nanoparticles
cannot be easily predicted. In this regard, SLN surface composition is a key factor in their cargo
internalization pathway and these mechanisms should be analyzed in order to control drug delivery.
Combination of drug delivery systems with molecules to develop smart strategies to improve
and drive therapeutic drugs is one of the most recurrent approaches in drug nanodelivery. In fact, this
strategy is currently applied not only to nanocarriers, but also to devices and even to the therapeutic
molecule itself [41–43]. It has been observed that selection of proper molecules of DDS improve
the selected delivery of the cargo to specific organelles [44]. Therefore, smart design of the surface
of nanocarriers would lead to regulation of the internalization and intracellular fate of the drug.
In particular, PEG coating has been extensively applied in the development of many DDS because
it improves many relevant characteristics such as stability or biocompatibility, but especially for the
development of stealth DDS. Several approaches have been developed incorporating PEG to SLN in
order to improve bioavailability [19,45] or to avoid immune cell recognition [46]. Unfortunately, these
effects depend on different factors such as PEG size, density, conformation or anchoring molecule [22,47]
and, therefore, all these parameters need to be adjusted for each particular case in order to obtain the
aforementioned improvements.
In this work, we developed and characterized SLN with different amounts of PE–PEG coatings
and we have observed no significant differences among their physicochemical properties. For instance,
the slight reduction of ζ-potential could indicate that the surface of the SLN was only partially modified
by PE–PEG as reported by other authors [48]. Nonetheless, PE–PEG presence seems to be enough to
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reduce SLN toxicity in a cell type dependent manner. Regarding intracellular distribution of SLN and
PEG–SLN, we have not observed differences between SLN and PEG-coated SLN.
In order to analyze cell mechanisms by which SLN are incorporated we have applied most widely
used pharmacological inhibitors of the main endocytosis pathways. Chlorpromazine selectively
inhibits clathrin-coated pit formation [49] but it has been observed that high concentrations of this
inhibitor can alter membrane characteristics [50]. Filipin inhibits caveolae-mediated endocytosis
because it is a membrane disruptor that binds preferentially to cholesterol [51] and therefore it could
also affect other cholesterol-dependent uptake mechanisms such as flotillin-dependent endocytosis,
GTPase regulator associated with focal adhesion kinase-1 (GRAF1)-dependent endocytosis, adenosine
diphosphate-ribosylation factor 6 (Arf6)-dependent endocytosis and RhoA-dependent endocytosis [52].
These endocytic pathways are relatively recently discovered mechanisms that take place in lipid
rafts. Cytochalasin D inhibits actin polymerization [53], thus, inhibiting both micropinocytosis and
phagocytosis. Nonetheless, it can potentially affect to other mechanisms where actin polymerization
is involved, such as GRAF1-dependent endocytosis or RhoA dependent endocytosis. Thus, further
experiments should be addressed in order to clearly elucidate cell internalization mechanisms and
their contribution to the endocytosis of each SLN type. Interference RNA technology or combination
of different pharmacological inhibitors are some of the available methods to unravel this issue [52].
The elucidation of cell internalization mechanism would clear up more details about intracellular fate
of the cargo and subsequently, about the improvement of the efficiency of the delivered drug.
In our system, clathrin-mediated endocytosis was enhanced in PEG-coated SLN, suggesting that
PEG-coating does not impair cell recognition. Therefore, interactions between SLN and membrane
proteins are still functional, allowing active cell internalization. In our hands, PE–PEG coating does
not change the interaction pattern of SLN and monocytes and cell internalization mechanisms seem to
be similar for SLN and PEG–SLN. Conversely, we observed improved nanoparticle incorporation of
PEG–SLN in SCC-25 cells in comparison to SLN. In this cell type, SLN were mainly incorporated by a
non-active cell internalization mechanism, probably by the aforementioned unspecific “kiss-and-run”
mechanism. This can be the reason why the SLN internalization is barely reduced by endocytosis
inhibitors in SCC-25 cell line. Arranja and co-workers reported that PEGgylation of SLN showed
altered cell internalization pattern, leading to higher therapeutic efficacy [54]. This property of
PEG–SLN could be highly interesting for chemotherapeutic drugs because it is well known that cell
internalization mechanism is crucial for the efficiency of the drug and for reduction of negative side
effects and multidrug resistance mechanisms (i.e., P-glycoproteins).
Taking into account these promising results, more experiments should be addressed in the future
to understand the reasons why this effect is so different in these cell lines. That information could
shed light on the internalization mechanisms and on the influence of characteristics such as cell size
and membrane topology that could be relevant factors in this context. The biased cell incorporation
mechanism showed by coated or non-coated SLN led us to study the effect of surface coating on
drug efficiency. We prepared ATRA loaded SLN and PEG–SLN because ATRA is a well-known
chemotherapeutic agent and it has already been reported that incorporation of ATRA into SLN
improves drug stability and solubility [55]. Surface modification of SLN with PE–PEG reduced slightly
drug EE, an effect that was also observed by other authors [41]. Nonetheless, developed nanoparticle
suspensions preset good characteristics as DDS.
Next we wanted to investigate how the PEG-coating affect the chemotherapeutic activity of ATRA.
To do so cytotoxicity of ATRA-loaded PEG–SLN in SCC-25 cells was studied. Our results show that
ATRA incorporated into SLN had higher cytotoxic effect than free ATRA, from 17.48% to 37.5% of
cell death in the less favorable condition (5 µM of ATRA). Even more, PEG–SLN showed a striking
effect on the cytotoxic effect of ATRA reaching up to 79.28% of cell death for 20 µM. This improvement
allows applying lower doses of ATRA to reach equivalent antitumoral effects, alleviating side effects.
In view of the changes in the cell incorporation mechanism induced by PEG surface modification,
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we can think that one of the reasons for this improvement on ATRA effect can rely on the different
incorporation route for free or nanoparticle driven drug.
In sum, loading ATRA into SLN provides good alternatives for the use of free ATRA in
chemotherapy not only because organic solvents can be avoided but also because surface modification
with PE–PEG increases significantly the effect of ATRA in an oral carcinoma cell line.
5. Conclusions
PEG-covering did not affect physicochemical characteristics of SLN and PEG–SLN presented
suitable characteristics to be applied as DDS. We have also observed that addition of PE–PEG did not
impair phagocytosis of SLN by monocytic cells, but it changed interactions with cell membranes in
epithelial cells, enhancing active internalization pathways. Interestingly, PEG–SLN increases all-trans
retinoic acid treatment efficiency, as this formulation showed a better cytotoxicity effect than retinoic
acid into SLN or in solution. In this work, we have developed an appropriate PE–PEG coating of SLN
that improves the antitumoral treatment efficiency of all-trans retinoic acid. We can conclude that SLN
are very versatile nanocarriers that can be tailored to achieve improvement in the efficiency of a given
therapeutic treatment.
Supplementary Materials: The following are available online at http://www.mdpi.com/2079-4991/9/3/464/s1,
Figure S1: TEM micrographs of the SLN under study, Figure S2: Particle size, polydispersity index and ζ-potential
values of SLN with different initial ATRA amounts, Figure S3: Determination of ATRA entrapment efficiency (EE)
in different SLN suspensions and Figure S4: Particle size, polydispersity index and ζ-potential values of SLN with
1 mg of initial ATRA, with or without PE–PEG.
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